CatalystMarker
← board

BCTXZ

distress 9/10 · high distress / dilution risk
$0.10-4%today-34% from 52w high
briacell.comWest Vancouver, BC
Revenue
pre-revenue
Liquidity
$23M
Runway
0.8 yrs
Shares 1y
+362%

Price & events

-33.8% over 6M
$0.10$0.12$0.14Mar 26May 26Jul 26398kdilution: 424B5 offering (2026-06-02)financing: 8-K private_placement (2026-06-03)
CatalystRating changeDilutionFinancingdashed = today
-3.9%
1D
-3.9%
1W
-16.4%
1M
-16.4%
3M
6M
1Y
2Y
5Y
-33.8%
All

Overview

Market Cap
$835.18K
Volume
1.06K
52 Week Range
$0.10 – $0.14
Total Shares
8.70M
Float Shares
7.86M
RVOL
0.04x
Beta
1.54

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 8,699,787 · 3 offerings/1y · 1 PIPEs
  • 2026-06-038-Kprivate_placement
  • 2026-06-02424B5offering
  • 2026-01-158-Kmaterial_agreement
  • 2026-01-14424B4offering
  • 2026-01-13EFFECTshelf_effective
  • 2025-12-23S-1shelf_registration
  • 2025-12-23FWPoffering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.